These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 17645835)

  • 1. Phase I trial of an enhanced prostate-specific antigen-based vaccine and anti-CTLA-4 antibody in patients with metastatic androgen-independent prostate cancer.
    Theoret MR; Arlen PM; Pazdur M; Dahut WL; Schlom J; Gulley JL
    Clin Genitourin Cancer; 2007 Jun; 5(5):347-50. PubMed ID: 17645835
    [No Abstract]   [Full Text] [Related]  

  • 2. Synergistic antitumor effect of chemotactic-prostate tumor-associated antigen gene-modified tumor cell vaccine and anti-CTLA-4 mAb in murine tumor model.
    Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
    Immunol Lett; 2007 Nov; 113(2):90-8. PubMed ID: 17913245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer.
    Gulley J; Chen AP; Dahut W; Arlen PM; Bastian A; Steinberg SM; Tsang K; Panicali D; Poole D; Schlom J; Michael Hamilton J
    Prostate; 2002 Oct; 53(2):109-17. PubMed ID: 12242725
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of PROSTVAC immunotherapy in prostate cancer.
    Singh P; Pal SK; Alex A; Agarwal N
    Future Oncol; 2015; 11(15):2137-48. PubMed ID: 26235179
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Future directions in tumor immunotherapy: CTLA4 blockade.
    Gulley JL; Dahut WL
    Nat Clin Pract Oncol; 2007 Mar; 4(3):136-7. PubMed ID: 17327854
    [No Abstract]   [Full Text] [Related]  

  • 6. A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer.
    Small EJ; Tchekmedyian NS; Rini BI; Fong L; Lowy I; Allison JP
    Clin Cancer Res; 2007 Mar; 13(6):1810-5. PubMed ID: 17363537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical protocol: phase I study of an adenovirus/prostate-specific antigen vaccine in men with metastatic prostate cancer.
    Lubaroff DM; Konety B; Link BK; Ratliff TL; Madsen T; Shannon M; Ecklund D; Williams RD
    Hum Gene Ther; 2006 Feb; 17(2):220-9. PubMed ID: 16454655
    [No Abstract]   [Full Text] [Related]  

  • 8. Pitfalls or promise in prostate cancer immunotherapy-which is winning?
    Slovin SF
    Cancer J; 2008; 14(1):26-34. PubMed ID: 18303480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-cytotoxic T lymphocyte antigen-4 (CTLA-4) immunotherapy for the treatment of prostate cancer.
    Thompson RH; Allison JP; Kwon ED
    Urol Oncol; 2006; 24(5):442-7. PubMed ID: 16962497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial.
    Madan RA; Mohebtash M; Arlen PM; Vergati M; Rauckhorst M; Steinberg SM; Tsang KY; Poole DJ; Parnes HL; Wright JJ; Dahut WL; Schlom J; Gulley JL
    Lancet Oncol; 2012 May; 13(5):501-8. PubMed ID: 22326924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Postoperative rehabilitation of patients with dyshormonal hyperplasia of the prostate].
    Georgiadi-Avdienko KA; Mutchaev KIu; Kurtaev OSh
    Vopr Kurortol Fizioter Lech Fiz Kult; 2007; (5):26-9. PubMed ID: 18050723
    [No Abstract]   [Full Text] [Related]  

  • 12. The potential for prostate cancer immunotherapy.
    Rini BI; Small EJ
    Crit Rev Oncol Hematol; 2003 Jun; 46 Suppl():S117-25. PubMed ID: 12850532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combination immunotherapy of primary prostate cancer in a transgenic mouse model using CTLA-4 blockade.
    Hurwitz AA; Foster BA; Kwon ED; Truong T; Choi EM; Greenberg NM; Burg MB; Allison JP
    Cancer Res; 2000 May; 60(9):2444-8. PubMed ID: 10811122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prostate cancer immunotherapy.
    McNeel DG
    Curr Opin Urol; 2007 May; 17(3):175-81. PubMed ID: 17414515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combining active immunotherapy with immune checkpoint blockade for the treatment of advanced prostate cancer.
    Antonarakis ES
    Asian J Androl; 2012 Jul; 14(4):520-1. PubMed ID: 22580638
    [No Abstract]   [Full Text] [Related]  

  • 16. Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer.
    Tarhini AA; Kirkwood JM
    Curr Opin Mol Ther; 2007 Oct; 9(5):505-14. PubMed ID: 17932815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for the development of PSA-based vaccines for the treatment of advanced prostate cancer.
    Arlen PM; Gulley JL; Tsang KY; Schlom J
    Expert Rev Vaccines; 2003 Aug; 2(4):483-93. PubMed ID: 14711334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breaking immune tolerance by targeting CD25+ regulatory T cells is essential for the anti-tumor effect of the CTLA-4 blockade in an HLA-DR transgenic mouse model of prostate cancer.
    Klyushnenkova EN; Riabov VB; Kouiavskaia DV; Wietsma A; Zhan M; Alexander RB
    Prostate; 2014 Oct; 74(14):1423-32. PubMed ID: 25111463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Metastatic prostate cancer: new insights and developments].
    Lorch A
    Dtsch Med Wochenschr; 2013 Apr; 138(14):703-6. PubMed ID: 23533034
    [No Abstract]   [Full Text] [Related]  

  • 20. Systemic therapeutic strategies for prostate cancer.
    Nelson WG
    Clin Adv Hematol Oncol; 2005 Aug; 3(8):619-21. PubMed ID: 16167046
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.